Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies.

Autor: Rotundo, Salvatore, Borelli, Massimo, Scaglione, Vincenzo, Lionello, Rosaria, Biamonte, Flavia, Olivadese, Vincenzo, Quirino, Angela, Morrone, Helen Linda, Matera, Giovanni, Costanzo, Francesco Saverio, Russo, Alessandro, Trecarichi, Enrico Maria, Torti, Carlo, IDTM UMG COVID-19 Group, Serapide, Francesca, Tassone, Bruno, Fusco, Paolo, Davoli, Chiara, La Gamba, Valentina, Berardelli, Lavinia
Předmět:
Zdroj: Clinical & Experimental Medicine; Nov2023, Vol. 23 Issue 7, p3681-3687, 7p
Abstrakt: In a convenience sample of 93 patients treated with monoclonal antibodies (moAbs) against SARS-CoV-2, the interleukin-62/lymphocyte count ratio (IL-62/LC) was able to predict clinical worsening both in early stages of COVID-19 and in oxygen-requiring patients. Moreover, we analysed 18 most at-risk patients with asymptomatic or mild disease treated with both moAbs and antiviral treatment and found that only 2 had clinical progression, while patients with a similar risk were reported to have an unfavourable outcome in most cases from recent data. In only one of our 18 patients, clinical progression was attributable to COVID-19, and in the other cases, clinical progression was observed despite IL-62/LC being above the risk cut-off. In conclusion, IL-62/LC may be a valuable method to identify patients requiring more aggressive treatments both in earlier and later stages of the disease; however, most at-risk patients can be protected from clinical worsening by combining moAbs and antivirals, even if levels of the IL-62/LC biomarker are lower than the risk cut-off. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: